Kodiak Sciences Inc Banner Image

Kodiak Sciences Inc

  • Ticker KOD
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Kodiak Sciences Inc Logo Image
  • 11-50 Employees
  • Based in Palo Alto, California
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, they are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Their ABC Platform™ usesMore molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, a leading cause of blindness in elderly patients, and diabetic eye diseases, a leading cause of blindness in working-age patients.
Kodiak Sciences Inc

Most Recent Responsibility Report

Kodiak Sciences Inc

Kodiak Sciences Inc does not currently have any hardcopy reports on ResponsibilityReports.com. Click the button below to request a report when hardcopies become available.

Request Information
Our service enables potential investors to review the most recent and archived Kodiak Sciences Inc Sustainability Report, Kodiak Sciences Inc Corporate Social Responsibility Report, Kodiak Sciences Inc CSR Report, Kodiak Sciences Inc Corporate Responsibility, Kodiak Sciences Inc CR Report, Kodiak Sciences Inc Citizenship Report, Kodiak Sciences Inc ESG Report, and Kodiak Sciences Inc Environmental Report online.
Kodiak Sciences Inc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!